FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2572580147> ?p ?o ?g. }

• W2572580147 abstract "Abstract Abstract 2228 Background: Eltrombopag is an oral thrombopoietin receptor agonist for the treatment of immune thrombocytopenic patients who are refractory to the medications including corticosteroid. In RAISE study (The Lancet 2011: 377; 393–402), 79% patients in the eltrombopag group responded to treatment at least once during the study. However, 7% of eltrombopag-treated patients had increase of alanine aminotransferase (ALT) concentration and 4% of total bilirubin. The mechanism of eltrombopag-induced hepatobiliary toxicity remains unknown. In this study, we evaluated the effects of eltrombopag on hepatocytes using HepG2, human hepatocellular carcinoma cell line. Method: Cell proliferation was analyzed by MTT assay. Analysis of apoptosis/necrosis was analyzed by flow cytometry assay using Annexin V and propium iodide (PI) (Annexin-/PI-, viable cells; Annexin+/PI-, early apoptosis cells; Annexin+/PI+, late apoptosis and necrosis cells; Annexin-/PI+, late necrosis cells). Reduced glutathione was measured by DTNB colorimetric method. Murine hepatoma cell line Hepa 1–6 and murine normal liver derived cell line NCTC clone 1469 were also used in this study. Results: HepG2 was incubated with eltrombopag for 72 hrs and then MTT assay was performed. Figure 1a showed the growth inhibition curve of HepG2. HepG2 growth was suppressed by eltrombopag in a dose dependent manner (Figure 1a: without NAC, 12.5 μM 44.3 ± 8.7 %). In the addition of N-acetylcysteine (NAC) canceled the inhibitory effect (Figure 1a: with NAC 10mM: 60.4 ± 22.3 % at 12.5μM eltrombopag, p<0.05). To investigate whether this suppression was due to apoptosis or necrosis, we used PI/ Annexin V assay using flow cytometry. Figure 1b showed that each cell fraction after 72 hrs incubation with eltrombopag. PI positive and PI negative fraction was markedly increased (0μM: 0.7 ± 0.4%, 12.5 μM: 8.0 ± 6.0% p<0.01, 25μM: 39.6 ± 12.2% p<0.001). To confirm that the inhibitory effects of eltrombopag might be due to necrosis, we used IM-54, which is inhibitory molecule against oxidative stress induced necrosis, in MTT assay and PI/ Annexin V assay. As shown in Figure 2 a and 2 b, IM-54 canceled the inhibitory effects of eltrombopag in MTT assay (IM-54 0μM: 18.3 ± 7.5 %, IM-54 10 μM: 33.9 ± 10.6 % at eltrombopag 25μM, p<0.01) and PI/Annexin V assay (IM-54 0μM: 48.3 ± 12.4 %, IM-54: 10 μM 74.2 ± 8.3 % in PI/Annexin V double negative fraction at eltrombopag 25μM, p<0.01). The addition of Caspase-Inhibitor III (Boc-D-FMK) did not cancel the growth inhibition by eltrombopag in MTT assey. We measured GSH concentration of HepG2 cells. After the treatment of eltrombopag for 72 hrs, GSH decreased at 12.5μM of eltrpmbopag, however IM-54 restored the GSH concentration (83 mM at IM-54 0μM and eltrombopag 0 μM, IM-54 0 μM: 42.0 mM and IM-54 10μM: 83.3 mM at eltrombopag 12.5μM). Similar data were obtained in the study using Hepa 1–6 and NCTC clone 1469. Conclusion: Basic structure of eltrombopag is similar to that of 3-bipheyl-carboxylic acid, which is a strong oxidizing agent. Taken together, eltrombopag have an oxidative stress on hepatocytes to result in hepatotoxicity. Disclosures: No relevant conflicts of interest to declare." @default.
• W2572580147 created "2017-01-26" @default.
• W2572580147 creator A5012499237 @default.
• W2572580147 creator A5021620288 @default.
• W2572580147 creator A5033377638 @default.
• W2572580147 creator A5034065557 @default.
• W2572580147 creator A5076101717 @default.
• W2572580147 creator A5086856159 @default.
• W2572580147 date "2011-11-18" @default.
• W2572580147 modified "2023-09-29" @default.
• W2572580147 title "Hepatotoxicity During Eltrombopag Administration Might Be Due to Necrosis of Hepatocytes" @default.
• W2572580147 doi "https://doi.org/10.1182/blood.v118.21.2228.2228" @default.
• W2572580147 hasPublicationYear "2011" @default.
• W2572580147 type Work @default.
• W2572580147 sameAs 2572580147 @default.
• W2572580147 citedByCount "0" @default.
• W2572580147 crossrefType "journal-article" @default.
• W2572580147 hasAuthorship W2572580147A5012499237 @default.
• W2572580147 hasAuthorship W2572580147A5021620288 @default.
• W2572580147 hasAuthorship W2572580147A5033377638 @default.
• W2572580147 hasAuthorship W2572580147A5034065557 @default.
• W2572580147 hasAuthorship W2572580147A5076101717 @default.
• W2572580147 hasAuthorship W2572580147A5086856159 @default.
• W2572580147 hasConcept C126322002 @default.
• W2572580147 hasConcept C153911025 @default.
• W2572580147 hasConcept C159654299 @default.
• W2572580147 hasConcept C190283241 @default.
• W2572580147 hasConcept C202751555 @default.
• W2572580147 hasConcept C203014093 @default.
• W2572580147 hasConcept C2775934118 @default.
• W2572580147 hasConcept C2776200302 @default.
• W2572580147 hasConcept C2780588981 @default.
• W2572580147 hasConcept C2780670749 @default.
• W2572580147 hasConcept C2993327898 @default.
• W2572580147 hasConcept C31573885 @default.
• W2572580147 hasConcept C503630168 @default.
• W2572580147 hasConcept C553184892 @default.
• W2572580147 hasConcept C55493867 @default.
• W2572580147 hasConcept C62112901 @default.
• W2572580147 hasConcept C71924100 @default.
• W2572580147 hasConcept C86803240 @default.
• W2572580147 hasConcept C88634738 @default.
• W2572580147 hasConcept C98274493 @default.
• W2572580147 hasConceptScore W2572580147C126322002 @default.
• W2572580147 hasConceptScore W2572580147C153911025 @default.
• W2572580147 hasConceptScore W2572580147C159654299 @default.
• W2572580147 hasConceptScore W2572580147C190283241 @default.
• W2572580147 hasConceptScore W2572580147C202751555 @default.
• W2572580147 hasConceptScore W2572580147C203014093 @default.
• W2572580147 hasConceptScore W2572580147C2775934118 @default.
• W2572580147 hasConceptScore W2572580147C2776200302 @default.
• W2572580147 hasConceptScore W2572580147C2780588981 @default.
• W2572580147 hasConceptScore W2572580147C2780670749 @default.
• W2572580147 hasConceptScore W2572580147C2993327898 @default.
• W2572580147 hasConceptScore W2572580147C31573885 @default.
• W2572580147 hasConceptScore W2572580147C503630168 @default.
• W2572580147 hasConceptScore W2572580147C553184892 @default.
• W2572580147 hasConceptScore W2572580147C55493867 @default.
• W2572580147 hasConceptScore W2572580147C62112901 @default.
• W2572580147 hasConceptScore W2572580147C71924100 @default.
• W2572580147 hasConceptScore W2572580147C86803240 @default.
• W2572580147 hasConceptScore W2572580147C88634738 @default.
• W2572580147 hasConceptScore W2572580147C98274493 @default.
• W2572580147 hasLocation W25725801471 @default.
• W2572580147 hasOpenAccess W2572580147 @default.
• W2572580147 hasPrimaryLocation W25725801471 @default.
• W2572580147 hasRelatedWork W157435976 @default.
• W2572580147 hasRelatedWork W2057030795 @default.
• W2572580147 hasRelatedWork W2330478069 @default.
• W2572580147 hasRelatedWork W2337084509 @default.
• W2572580147 hasRelatedWork W2356822353 @default.
• W2572580147 hasRelatedWork W2361104082 @default.
• W2572580147 hasRelatedWork W2362514185 @default.
• W2572580147 hasRelatedWork W2368060897 @default.
• W2572580147 hasRelatedWork W2371149335 @default.
• W2572580147 hasRelatedWork W2376575701 @default.
• W2572580147 hasRelatedWork W2378536668 @default.
• W2572580147 hasRelatedWork W2378914185 @default.
• W2572580147 hasRelatedWork W2384613559 @default.
• W2572580147 hasRelatedWork W2387091447 @default.
• W2572580147 hasRelatedWork W2390514710 @default.
• W2572580147 hasRelatedWork W2408815858 @default.
• W2572580147 hasRelatedWork W2410955998 @default.
• W2572580147 hasRelatedWork W2564010876 @default.
• W2572580147 hasRelatedWork W2586216527 @default.
• W2572580147 hasRelatedWork W261308446 @default.
• W2572580147 isParatext "false" @default.
• W2572580147 isRetracted "false" @default.
• W2572580147 magId "2572580147" @default.
• W2572580147 workType "article" @default.